Lumos Pharma Inc. (LUMO)
NASDAQ: LUMO
· Real-Time Price · USD
4.34
0.00 (0.00%)
At close: Dec 11, 2024, 10:00 PM
Lumos Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 726K | 488K | 165K | 826K | 7K | 527K | 691K | 512K | 497K | 403K | 111K | 220K | n/a | 10K | n/a |
Cost of Revenue | n/a | 2K | 2K | 18K | 8K | 9K | 9K | 35K | n/a | n/a | 12K | n/a | 10K | n/a | 170K |
Gross Profit | 726K | 486K | 163K | 808K | -1K | 518K | 682K | 477K | 497K | 403K | 99K | 220K | -10K | 10K | -170K |
Operating Income | -7.64M | -7.82M | -10.86M | -10M | -8.93M | -9.64M | -8.04M | -8.84M | -7.55M | -7.92M | -7.73M | -6.57M | -7.5M | -8.66M | -8.62M |
Interest Income | 168K | 70K | 158K | 293K | 446K | 559K | 570K | 503K | 292K | 74K | 5K | 5K | 2K | 2K | 3K |
Pretax Income | -7.47M | -7.55M | -10.44M | -9.46M | -8.3M | -8.96M | -7.35M | -8.26M | -7.25M | -7.84M | -7.72M | -6.28M | -7.49M | -8.67M | -8.63M |
Net Income | -7.47M | -7.55M | -10.44M | -9.46M | -8.3M | -8.93M | -6.66M | -7.67M | -7.25M | -7.76M | -7.71M | -5.64M | -7.49M | -8.67M | -8.63M |
Selling & General & Admin | 4.21M | 3.68M | 3.78M | 4.16M | 3.89M | 4.15M | 4.36M | 4.49M | 3.92M | 3.68M | 3.62M | 3.43M | 3.38M | 4.56M | 3.96M |
Research & Development | 4.15M | 4.63M | 7.25M | 6.66M | 5.05M | 6.02M | 4.37M | 4.86M | 4.13M | 4.64M | 4.22M | 3.36M | 4.11M | 4.11M | 4.66M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 72K | 7K | 6K | 6K | n/a | 7K | -8K | 20K |
Operating Expenses | 8.37M | 8.31M | 11.03M | 10.81M | 8.94M | 10.17M | 8.73M | 9.35M | 8.05M | 8.33M | 7.84M | 6.79M | 7.5M | 8.67M | 8.62M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 74K | n/a | n/a | n/a | n/a | 37K |
Selling & Marketing Expenses | n/a | -2K | -2K | -18K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 8.37M | 8.31M | 11.03M | 10.83M | 8.94M | 10.17M | 8.73M | 9.35M | 8.05M | 8.33M | 7.84M | 6.79M | 7.5M | 8.67M | 8.62M |
Income Tax Expense | n/a | n/a | -41.28K | n/a | -8K | -29K | -689K | -588K | n/a | -80K | -11K | -636K | 7K | -8K | 57K |
Shares Outstanding (Basic) | 8.33M | 8.11M | 8.1M | 8.1M | 7.98M | 8.16M | 8.24M | 8.27M | 8.39M | 8.36M | 8.36M | 8.34M | 8.32M | 8.73M | 8.32M |
Shares Outstanding (Diluted) | 8.33M | 8.11M | 8.1M | 8.1M | 7.98M | 8.16M | 8.24M | 8.27M | 8.39M | 8.37M | 8.36M | 8.36M | 8.36M | 8.73M | 8.32M |
EPS (Basic) | -0.9 | -0.93 | -1.29 | -1.17 | -1.04 | -1.09 | -0.81 | -0.93 | -0.86 | -0.93 | -0.92 | -0.68 | -0.9 | -0.99 | -1.04 |
EPS (Diluted) | -0.9 | -0.93 | -1.29 | -1.17 | -1.04 | -1.09 | -0.81 | -0.93 | -0.86 | -0.93 | -0.92 | -0.67 | -0.9 | -0.99 | -1.04 |
EBITDA | -7.64M | -7.82M | -10.86M | -9.99M | -8.92M | -9.63M | -8.03M | -8.8M | -7.55M | -7.84M | -7.72M | -6.76M | -7.48M | -8.65M | -8.42M |
EBIT | -7.64M | -7.82M | -10.86M | -10M | -8.93M | -9.64M | -8.04M | -9.22M | -7.55M | -7.84M | -7.73M | -6.59M | -7.49M | -8.67M | -8.59M |
Depreciation & Amortization | n/a | 2K | 2K | 18K | 8K | 9K | 9K | 35K | 4K | -2K | 12K | 10K | 10K | 83K | 170K |